CELLECTIS S.A. ANNOUNCES AN AGREEMENT WITH SHIRE PHARMACEUTICALS IN THE FIELD OF GENE ACTIVATED PROTEINS

A A

Cellectis S.A. announced today that they entered into an agreement with Shire Pharmaceuticals, by which Cellectis will grant Shire a worldwide non-exclusive commercial license relating to it site-directed genome engineering technologies for creating and developing genetically engineered cells to produce certain gene activated biopharmaceuticals. Financial terms and conditions of the agreement were not disclosed.

Biotech Intelligence (http://www.biotech-intelligence.com/html/html/8fc644fc5e96fae3fffb938c60a3eb0c.html)